The company's real-time PCR platform allows users to detect and assess single nucleotide polymorphisms in genes related to autoimmune diseases, enhancing response rates for autoimmune disorder treatment. GenQual Corporation, founded in 2009 and based in Des Moines, Washington, focuses on developing biomarker diagnostics for disease detection and diagnosis, particularly in autoimmune, inflammatory, and cancer therapies.